Based on these pieces of evidence, it is possible to use elevated plasma concentrations of CRP, IL-6, resistin, TNF-α, and reduced levels of NO and adiponectin as markers to predict the development and progression of type 2 DM, hypertension, and coronary heart disease (207–210), whereas reductions in their levels (CRP, IL-6, and TNF-α) and increase in those of adiponectin and NO induced by diet control, exercise, and statin therapy may suggest a better prognosis in these patients. The gene discussed is ADIPOQ; the disease is hypertensive disorder.